Dr. Kenneth Fong is currently the founder and chairman of Kenson Ventures, LLC, a company that specializes in crafting development strategy for early-stage biotech companies. Under his leadership, companies that were acquired or went public between 2007 and 2016 are: SABiosciences (to Qiagen), DHI (to Quidel), Fermenta (to ThermoFisher), Panomics (to Affymetrix), Epitomics (to Abcam), ACD (to Bio-Techne), Bioform (IPO) and Optimer (IPO). Prior to establishing Kenson, Ken founded and served as CEO of Clontech Laboratories (1984-1999), which was acquired by Becton Dickinson in 1999. Clontech, a leader in the molecular/cell biology market, was also the largest of its kind founded by an Asian American (400 people, including 65 PhD scientists). Currently, Ken sits on the Board of 5 biotech companies, ranging from immunotherapy to medical tool companies.
Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (ca 2,000 members, 2007-09) and President of the Bay Area AAMA (1987). He was also a member of the Board of Trustees of California State University (2006-2013), the Advisory Board of the College of Science and Engineering at San Francisco State, Board of Associates at the Whitehead Biomedical Institute. Ken has many other philanthropic interests. He was one of the lead supporters for the San Jose Tech Museum, the Chinese Historical Society in San Francisco, the Bioengineering Auditorium at UC San Diego and the Indiana University graduate Seminar Programs. He has provided a number of scholarships to San Francisco State University, Peking University and the California State University students (Kenneth Fong-Hearst endowed Scholarships). In 2006, he was also involved in establishing the Fong Optometry and Medical Library at UC Berkeley and more recently an endowed professorship at Stanford University and a technology translation endowment fund at San Francisco State University. Ken received his Ph.D. from Indiana University.